UBS Maintains 75% Success Probability for Ocular Therapeutix's Axpaxli in Wet AMD
UBS analysts reaffirmed a 75% probability of success for Ocular Therapeutix's Axpaxli in treating wet age-related macular degeneration following a competitor's trial results.